ArticleJournal of controlled release : official journal of the Controlled Release Society2012
Challenges and opportunities in the advancement of nanomedicines.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 106 citations in OpenAlex.
- Nanoparticle carriers in the treatment of intracellular bacterial infections: Current approaches and challenges.International journal of pharmaceutics: X · 2026Review
- Synthesis of nanoparticles via microfluidic devices and integrated applications.Mikrochimica acta · 2023Review
- Recent Biomedical Applications of Coupling Nanocomposite Polymeric Materials Reinforced with Variable Carbon Nanofillers.Biomedicines · 2023Review
- Molecular basis of transport of surface functionalised gold nanoparticles to pulmonary surfactant.RSC advances · 2022Article
- Designing Functional Bionanoconstructs for EffectiveBioconjugate chemistry · 2022Review
- Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment.Materials (Basel, Switzerland) · 2022Review
- High-Throughput Method for the Simultaneous Determination of Doxorubicin Metabolites in Rat Urine after Treatment with Different Drug Nanoformulations.Molecules (Basel, Switzerland) · 2022Article
- Mesoporous Carbon: A Versatile Material for Scientific Applications.International journal of molecular sciences · 2021Review
- Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art.Current neuropharmacology · 2021Review
- Antimicrobial photodynamic activity of gallium-substituted haemoglobin on silver nanoparticles.Nanoscale · 2020Article
- Combined Chemisorption and Complexation Generate siRNA Nanocarriers with Biophysics Optimized for Efficient Gene Knockdown and Air-Blood Barrier Crossing.ACS applied materials & interfaces · 2020Article
- Assessment of Intratumoral Doxorubicin Penetration after Mild Hyperthermia-Mediated Release from Thermosensitive Liposomes.Contrast media & molecular imaging · 2019Article
- Scalable synthesis and validation of PAMAM dendrimer-Bioengineering & translational medicine · 2018Article
- A feasible strategy for self-assembly of gold nanoparticlesRSC advances · 2018Article
- Micellization and Single-Particle Encapsulation with Dimethylammoniopropyl Sulfobetaines.ACS omega · 2017Article
- Mesoporous carbon nanomaterials in drug delivery and biomedical application.Drug delivery · 2017Review
- Early Development Challenges for Drug Products Containing Nanomaterials.The AAPS journal · 2017Article
- Where Are the Nanodrugs? An Industry Perspective on Development of Drug Products Containing Nanomaterials.The AAPS journal · 2016Review
- Bioaccumulation and Subchronic Toxicity of 14 nm Gold Nanoparticles in Rats.Molecules (Basel, Switzerland) · 2016Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Nanomedicine-based approaches to cancer treatment face several challenges that differ from those encountered by conventional medicines during clinical development. A systematic exploration of these issues has led us to identify the following needs and opportunities for further development: (1) robust and general methods for the accurate characterization of nanoparticle size, shape, and composition; (2) scalable approaches for producing nanomedicines with optimized bioavailability and excretion profiles; (3) particle engineering for maintaining low levels of nonspecific cytotoxicity and sufficient stability during storage; (4) optimization of surface chemistries for maximum targeted delivery and minimum nonspecific adsorption; (5) practical methods for quantifying ligand density and distributions on multivalent nanocarriers; and (6) the design of multifunctional nanomedicines for novel combination therapies with supportable levels of bioaccumulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.